AKT1 and melanoma: Using an NIH3T3 stable cell line expressing BRAFV600E and various melanoma cell lines (BRAF WT or V600E), we demonstrated that BRAFV600E not only suppresses MEK inhibitor or rapamycin-induced AKT pathway activation but also negatively regulates basal AKT pathway signaling.